Key Dosage Ranges and Standard Regimens
Artemisinin and artemisinin-based combination therapies (ACTs) are first-line treatments for uncomplicated Plasmodium falciparum malaria. Standard adult artemisinin-based regimens are designed to rapidly reduce parasitemia and prevent resistance. For artesunate, the WHO-recommended dose is 2.4 mg/kg intravenous or intramuscular at 0, 12, and 24 hours, then 2.4 mg/kg once daily thereafter. For artemether, the typical regimen is 150 mg twice daily for three days when taken orally. Artemisinin doses in fixed-dose ACT combinations vary by partner drug: artemether-lumefantrine, artesunate-amodiaquine, and artesunate-sulfadoxine-pyrimethamine each specify weight-banded dosing aligned to the artemisinin component. Children receive weight-adjusted doses to ensure therapeutic exposure and safety.
Weight-Banded Dosing and Calculation Guidance
Weight-band dosing simplifies administration in clinical and humanitarian settings. For oral artemether tablets (150 mg), approximate bands are: 5–9 kg: 50 mg twice daily; 10–14 kg: 75 mg twice daily; 15–19 kg: 100 mg twice daily; 20–24 kg: 125 mg twice daily; 25–29 kg: 150 mg twice daily; 30–34 kg: 175 mg twice daily; 35–39 kg: 200 mg twice daily; 40 kg and above: 150 mg twice daily. Intravenous artesunate uses exact weight (mg = kg × dose, usually 2.4 mg/kg). Accurate scales and calibrated equipment are essential to avoid under- or overdosing, particularly in resource-limited settings where malaria is most prevalent.
Comparing Standard Adult Dosing for Common ACT Formulations
| Formulation | Artemisinin Component | Typical Adult Dose (per administration) | Duration |
|---|---|---|---|
| Artesunate | Artesunate | 2.4 mg/kg IV/IM | Daily until 24h, then per WHO |
| Artesunate | Artesunate | 100 mg orally twice daily | 3 days (in some combinations) |
| Artemether | Artemether | 150 mg orally twice daily | 3 days |
| Artemether-lumefantrine | Artemether | 150/900 mg (25/150 lb weight-band) | Twice daily for 3 days |
| Artesunate-amodiaquine | Artesunate | 100/600 mg (weight-band aligned) | Daily for 3 days |
| Dihydroartemisinin-piperaquine | Dihydroartemisinin | 20 mg base (based on 65 kg) | Daily for 3 days |
Therapeutic Goals and Treatment Duration
Artemisinin derivatives achieve rapid parasite clearance and reduce transmission. Standard ACT courses typically last three days, completing the full course even after symptoms improve to prevent recrudescence and resistance. Monitoring parasitemia and clinical recovery is essential, especially in severe or complicated malaria where intravenous artesunate is indicated before switching to an oral ACT. In pregnancy, where appropriate ACT regimens are carefully selected, accurate dosing reduces maternal parasitemia and protects the fetus. Duration may vary slightly by region and regimen, so always follow local guidelines informed by WHO recommendations.
Safety Considerations and Contraindications
Artemisinin compounds are generally well tolerated at recommended doses. Common adverse effects include mild gastrointestinal upset, headache, and dizziness. Hypersensitivity reactions are rare but require discontinuation. Artesunate use in the first trimester of pregnancy is generally avoided unless benefits outweigh risks; later trimesters may use specific ACTs per national policy. Liver impairment may require dose adjustment for oral formulations; renal impairment typically does not necessitate adjustment but should be considered clinically. Drug interactions with other antimalarials or medications metabolized by the same pathways should be reviewed, particularly in co-endemic settings with multiple therapies.
Dosing in Special Populations and Resource-Limited Settings
In humanitarian emergencies and remote areas, accurate dosing without scales is challenging; therapeutic dose banding by weight range is common. Use calibrated devices and validated weight-based charts. For infants and neonates, where data are limited, consult specialized pediatric guidance and national malaria policies. Community health workers should adhere strictly to approved treatment protocols, verify drug quality, and avoid improvisation. Fixed-dose combinations reduce dosing complexity and error, improving adherence and outcomes. Whenever feasible, confirm weight and clinical status before administering artemisinin-based therapies to minimize risks of under- or overdosing.
Differences From Other Antimalarial Classes
Unlike chloroquine or older antimalarials, artemisinin derivatives act rapidly and are used primarily in combination to delay resistance. Quinine requires more frequent dosing and has more side effects, while atovaquone-proguanil has a different dosing schedule and contraindications. Mefloquine is used for prophylaxis and treatment in specific regions, with distinct dosing from artemisinins. Understanding these distinctions helps clinicians choose appropriate regimens and counsel patients on adherence and safety. Artemisinin-based regimens are preferred where resistance patterns and national policies support their use, and dosing must align with local guidelines.